type 1 diabetes mellitus 12
type 1 diabetes mellitus 12
Explore linked clinical trials. Standard reference: MONDO:001106828 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of SYS6088 in Patients With Advanced/Metastatic Solid Tumors | autosomal dominant Parkinson disease 4, neoplasm, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 1 / Phase 2 | 2026-10-05 | NCT07857135 | |
| Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, type 1 diabetes mellitus 12 | Recruiting | Phase 1 | 2026-09-25 | NCT07476326 | |
| Neoadjuvant Pembrolizumab and Porustobart in Resectable pMMR/MSS Colon Cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, Spinocerebellar Degenerations, brain disorder, central nervous system disorder, cerebellar disorder, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, hereditary disease, inherited neurodegenerative disorder, intestinal disorder, malignant colon neoplasm, neoplasm, nervous system disorder, neurodegenerative disease, spinal cord disorder, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 2 | 2026-09-08 | NCT07808151 | |
| Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting Sarcomas | Ewing sarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, bone disorder, connective tissue neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, sarcoma, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 1 / Phase 2 | 2026-08-26 | NCT03356782 | |
| A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors | neoplasm, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 1 | 2026-08-21 | NCT03530397 | |
| A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, type 1 diabetes mellitus 12, urinary system disorder | Active, not recruiting | Phase 1 | 2026-08-03 | NCT07000149 | |
| GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ) | Neoplasm Metastasis, Neoplasms by Site, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 1 / Phase 2 | 2026-07-31 | NCT07738341 | |
| Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenoma, epithelial neoplasm, lung disorder, lung neoplasm, malignant mesothelioma, mesothelial neoplasm, mesothelioma, neoplasm, pleural neoplasm, respiratory system disorder, respiratory tract neoplasm, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 2 | 2026-07-27 | NCT01843374 | |
| Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neoplasms by Site, Neoplasms, Multiple Primary, Thoracic Neoplasms, autosomal dominant Parkinson disease 4, bronchial neoplasm, bronchogenic carcinoma, endocrine system disorder, hereditary disease, hereditary neoplastic syndrome, lethal congenital contracture syndrome 2, lung disorder, lung neoplasm, malignant endocrine neoplasm, multiple endocrine neoplasia, multiple endocrine neoplasia type 2A, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, type 1 diabetes mellitus 12 | Recruiting | Phase 1 | 2026-07-22 | NCT05142189 | |
| Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, mismatch repair cancer syndrome 1, neoplasm, rectal disorder, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 1 / Phase 2 | 2026-06-24 | NCT05426005 | |
| Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC) | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, biliary tract cancer, biliary tract disorder, carcinoma, epithelial neoplasm, neoplasm, type 1 diabetes mellitus 12 | Recruiting | Phase 1 | 2026-05-08 | NCT06564623 | |
| IMMUNO-FIT Observational Study | Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, neoplasm, type 1 diabetes mellitus 12 | Recruiting | Not stated | 2026-04-28 | NCT07354971 | |
| PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC | Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, adenocarcinoma, carcinoma, epithelial neoplasm, lung adenocarcinoma, lung neoplasm, neoplasm, respiratory tract neoplasm, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 2 | 2026-02-17 | NCT07416058 | |
| Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm, type 1 diabetes mellitus 12 | Recruiting | Phase 2 | 2026-02-13 | NCT07410975 | |
| Montreal Immune-Related Adverse Events (MIRAE) Study | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, autoimmune disease, cancer, immune system disorder, neoplasm, type 1 diabetes mellitus 12 | Recruiting | Not stated | 2026-02-03 | NCT05139706 | |
| Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver disorder, neoplasm, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 2 | 2025-11-24 | NCT07243951 | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, autosomal dominant Parkinson disease 4, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 2 | 2025-09-04 | NCT05608044 | |
| A Single-Arm, Multicenter, Exploratory Clinical Study of TACE Combined With Iparomlimab and Tuvonralimab Injection (QL1706) and Lenvatinib for Perioperative Treatment of Resectable Hepatocellular Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 2 | 2025-08-20 | NCT07131501 | |
| A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC) | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm, type 1 diabetes mellitus 12 | Not yet recruiting | Phase 2 | 2025-08-17 | NCT07128251 | |
| A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, benign urinary system neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, neoplasm, renal cell carcinoma, type 1 diabetes mellitus 12, urinary system disorder | Active, not recruiting | Phase 1 | 2025-07-25 | NCT04522323 | |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm, type 1 diabetes mellitus 12 | Active, not recruiting | Phase 3 | 2025-07-08 | NCT05751928 | |
| Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study | type 1 diabetes mellitus 12 | Not yet recruiting | Phase 4 | 2025-06-04 | NCT07004335 | |
| AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma, type 1 diabetes mellitus 12 | Recruiting | Phase 2 | 2025-06-04 | NCT06494995 | |
| A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid Tumors | type 1 diabetes mellitus 12 | Not yet recruiting | Phase 1 | 2025-04-30 | NCT06934616 | |
| A Dose Escalation and Expansion Study of GIGA-564 in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | type 1 diabetes mellitus 12 | Recruiting | Phase 1 | 2025-04-10 | NCT06258304 |